- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03643744
Photodynamic Therapy-Induced Immune Modulation: Part III
This study is designed as a double-blinded proof of concept of feasibility study to define if the immunosuppression associated with photodynamic therapy (PDT) can be blocked by treatment with cyclo-oxygenase-2 (COX-2) inhibitor celecoxib in comparison to placebo. PDT consists of application of the photosensitizer 5-aminolevulinic acid followed by treatment with a blue light. PDT is used to treat pre-cancerous actinic keratosis on large areas of skin. These studies are a continuation of ongoing studies that indicate that the lipid mediator platelet-activating factor (PAF) is generated in skin following PDT, and that PDT suppresses the immune system. It is hypothesized that PDT-generated PAF results in the immunosuppression associated with PDT. Therefore, it is proposed that a treatment to block that immunosuppression could protect the patient undergoing PDT. Blockers of the PAF system are not currently commercially available. However research studies done at Wright State University using mice indicate that PAF- and PDT-induced immunosuppression is blocked by treatment with COX-2 inhibitors. This study is conducted as a proof of concept.
Study length and visit for subjects with actinic keratoses: The first part of the study is completed in 12 days then there are follow up visits at 6 and 12 months. There are a total of 6 separate visits to the research office.
Study length and visit for control subjects: The study is completed in 10 days. There are a total of 4 separate visits to the research office.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Fairborn, Ohio, United States, 45324
- Wright State Physicians
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Control Subjects:
- Adult age 45 or older
- Caucasian (Fair skin, Fitzpatrick types I and II)
- Ability to understand and consent to the instructions of the study
- Have access to stable transportation
Inclusion Criteria for Study Subjects:
- Wright State University dermatologist has prescribed PDT for the treatment of actinic damage (Presence of precancerous actinic keratoses whose treatment necessitates PDT with the BLU-U).
- Undergoing PDT on greater than 5% body surface area: face and scalp, face and dorsal surface of arms, face and chest, face and back, or dorsal surface of arms alone, chest alone, or back alone.
- Caucasian (Fair skin, Fitzpatrick types I and II)
- Adult-age 45 or older
- Ability to understand the informed consent and comply with instructions and have stable transportation.
Exclusion Criteria for All Subjects:
- PDT on less than 5% body surface area (eg, forehead)
- Present treatment with corticosteroids or Non-steroidal inflammatory drugs (e.g., cyclooxygenase inhibitors) within past 2 months (except low-dose 81 mg aspirin).
- On antioxidant supplements (e.g., vitamin C) for past 2 months
- Tanning bed use within last 3 months
- PDT treatments within last 3 months
- Significant health issues that could affect the immune system (e.g., uncontrolled Diabetes Mellitus, Rheumatoid arthritis, skin rashes, psoriasis) that could interfere with testing
- Pregnant or nursing
- No immunosuppression, and on no immunosuppressive medications or NSAIDS within past 30 days (except low-dose [81 mg daily] aspirin).
- No significant underlying diseases that could potentially interfere with the immune assays or cardiac or renal or liver problems.
- History of blood clot or hypercoagulable state or GI bleed/ulceration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PDT + Celecoxib
Patient receiving PDT taking 200mg celecoxib.
|
14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
|
Placebo Comparator: PDT + Placebo
Patient receiving PDT taking placebo.
|
14 placebo capsules taken 1 in the morning and 1 in the evening.
|
Active Comparator: Control + Celecoxib
Control subject not receiving PDT taking 200mg celecoxib.
|
14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
|
Placebo Comparator: Control + Placebo
Control subject not receiving PDT taking placebo.
|
14 placebo capsules taken 1 in the morning and 1 in the evening.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Photodynamic Therapy (PDT)-induced Systemic Immunosuppression From Baseline with Celecoxib Treatment.
Time Frame: Day 7
|
Investigator will assess change through clinical laboratory values and reactions to skin testing.
|
Day 7
|
Change From Baseline in the Number of Actinic Keratosis at 6 months.
Time Frame: 6 Months
|
Investigator will assess the number of actinic keratosis in the PDT-treated areas.
|
6 Months
|
Change From Baseline in the Number of Actinic Keratosis at 12 months.
Time Frame: 12 Months
|
Investigator will assess the number of actinic keratosis in the PDT-treated areas.
|
12 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffrey B Travers, MD, PhD, Wright State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Precancerous Conditions
- Keratosis, Actinic
- Keratosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- 06499
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on Celecoxib 200mg
-
Yooyoung Pharmaceutical Co., Ltd.CliPS Co., LtdCompletedOsteoarthritis, KneeKorea, Republic of
-
Yooyoung Pharmaceutical Co., Ltd.CliPSBnCRecruitingOsteoarthritis, KneeKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedOsteoarthritis HandKorea, Republic of
-
Peking University Third HospitalNot yet recruiting
-
Dr. Chris McGlory, PhDIovate Health Sciences International IncCompleted
-
Haudongchun Co., Ltd.UnknownBacterial Vaginosis | HUDC_VT | HaudongchunKorea, Republic of
-
JW PharmaceuticalCompletedErectile DysfunctionKorea, Republic of
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruitingAdvanced Hepatocellular CarcinomaChina
-
National Taiwan University HospitalRecruiting
-
Chong Kun Dang PharmaceuticalCompletedHealthy VolunteersKorea, Republic of